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We have shown previously that human glioblastoma multiforme cells vary in their ability to survive under hypoxic conditions.
Under oxygen limiting conditions, hypoxia-tolerant cells decrease their oxygen consumption rate whereas hypoxia-sensitive
cells continue to consume oxygen at a relatively steady rate until the oxygen supply becomes exhausted. We now show that
hypoxia-tolerant and hypoxia-sensitive cells exhibit distinct patterns of mitochondrial function in response to hypoxic challenge.
Hypoxia-tolerant cell lines retain stable mitochondrial membrane potential and ATP concentration when incubated under
oxygen limiting conditions. In addition, hypoxia-tolerant cell lines are consistently more sensitive to a wide spectrum of
inhibitors of mitochondrial function than are hypoxia-sensitive cells. In contrast, the hypoxia-sensitive cells are unable to
maintain stable mitochondrial membrane potential and ATP levels when incubated at reduced oxygen tension. These results
demonstrate signiﬁcant differences in the mitochondrial function between these two phenotypes and reinforce previous data
that suggest a regulatory role for mitochondria in the development of hypoxia tolerance.
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Glioblastoma multiforme (GBM) is the most common brain
tumour in adults. A pathognomonic feature of GBM is the
presence of extensive necrosis, and by inference, hypoxia (Nelson
et al, 1983; Wilden et al, 1987). Unlike normal brain tissue, which
is exquisitely sensitive to oxygen deprivation, brain tumour cells
can survive in relatively hypoxic microenvironments (Kinter et al,
1984). Hypoxic cells are relatively resistant to the killing effects
of ionizing radiation and some commonly used chemotherapeutic
agents, therefore, tumour cells that have acquired the ability to
adapt to low oxygen tensions may contribute to local treatment
failure.
Our laboratory has developed model systems to investigate the
mechanisms by which tumour cells adapt to variations in oxygen
supply. In vivo measurement of hypoxia in a variety of human
tumours by SPECT imaging of iodoazomycin arabinoside showed
an unusual pattern of heterogeneity in GBM tumours speciﬁcally
(Urtasun et al, 1996). Using cell lines derived from human GBM
biopsy material and human GBM xenografts, we have shown
that regional heterogeneity of oxygen consumption exists in
GBMs and that modulation of cellular respiration is an impor-
tant component of the hypoxia defence mechanisms utilized by
GBMs (Parliament et al, 1997; Franko et al, 1998; Allalunis-
Turner et al, 1999). However, individual tumours and cell lines
derived from them vary considerably in their ability to modulate
cellular respiration, with some being more or less proﬁcient than
others. For example, the hypoxia-tolerant cell lines M006x and
M059K signiﬁcantly reduce their rate of oxygen consumption
when incubated under moderately hypoxic conditions (2 or
0.6% oxygen) (Allalunis-Turner et al, 1999). M006 cells also
preserve their clonogenic potential after exposure to 4 days of
moderate hypoxia (0.6% oxygen). In contrast, hypoxia-sensitive
M010b cells maintain a steady oxygen consumption rate despite
decreased oxygen availability. Further, the ability of M010b cells
to form colonies when incubated under hypoxic conditions is
signiﬁcantly reduced despite the maintenance of a steady rate
of oxygen consumption.
Cells isolated from certain normal tissue, e.g., hepatocytes and
cardiomyocytes, also show the ability to modulate respiration in
response to hypoxic stress (Chandel et al, 1995, Chandel and Scha-
macker, 1999, 2000). In the case of heart and liver cells,
biochemical evidence indicates the primary involvement of mito-
chondria in adaptation to hypoxia. It has been suggested that
cytochrome c oxidase functions as a putative oxygen sensor that
mediates changes in respiration in response to changes in oxygen
concentration (Chandel et al, 1995, Chandel and Schamacker,
1999, 2000). We hypothesize that GBM cells capable of modulating
respiration in response to hypoxia utilize oxygen-sensing mechan-
isms similar to those identiﬁed in hepatocytes and cardiomyocytes.
Thus, differences in GBM cellular responses to hypoxia may be
mediated by differences in mitochondrial function as opposed to
cytosolic mechanisms or differences in mitochondrial mass or
biogenesis.
In this study, we compared the response of hypoxia-tolerant and
-sensitive human GBM cell lines to challenge with hypoxia as well
as agents that inhibit aerobic respiration. We also tested whether
demand for energy production under oxygen limiting conditions
would result in increased mitochondrial biogenesis or would
disrupt mitochondrial membrane potential. The results of these
studies show that variations in mitochondrial function exist
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chemical as well as hypoxic oxidative challenge.
MATERIALS AND METHODS
Cell lines and media
The origin and characterization of the GBM cell lines used in this
study have been published previously (Allalunis-Turner et al, 1992;
Parliament et al, 1997). The M010b, M006 and M059K cell lines
were derived directly from surgical specimens obtained from
patients with GBM. M006x is a cell line derived from M006
passage by through a mouse as a tumour xenograft. M006xLo
was obtained by incubating M006x cells at 0.6% oxygen for 2
weeks and culturing the surviving cells. All cell lines were cultured
in DMEM/F12 media supplemented with 10% foetal calf serum
and 1% L-glutamine and used in experiments at passage numbers
less than 40.
Generation of hypoxia
A de-gassing manifold designed by Dr Cameron Koch was used to
generate hypoxia (Koch and Painter, 1975). Brieﬂy, cells were
seeded onto 60 mm glass plates and allowed to attach for 24 h
at 378C in a standard incubator (5% CO2 in air). The plates were
then transferred to aluminium chambers from which air was evac-
uated and then replaced with 5% CO2/balance N2 until the desired
oxygen tension was achieved. The sealed, airtight canisters were
then incubated at 378C for the required amount of time.
ATP measurement
Intracellular ATP concentrations were measured using a
luciferase-based assay (ATP Bioluminescence Assay Kit, Roche)
according to manufacturer’s instructions. Brieﬂy, cells in expo-
nential growth phase were trypsinized, seeded onto 60 mm
glass dishes (10
5 cells per dish in 5 ml medium), and then incu-
bated at 378C for *20 h in a standard incubator alone or in
airtight chambers with the appropriate percentage of oxygen,
5% CO2/balance N2. The cells were then rinsed with PBS, tryp-
sinized, counted and transferred to a microcentrifuge tube on
ice. The cells were washed once in ice cold PBS, re-suspended,
and diluted in cold PBS to give 10
3 cells ml
71. Cell aliquots
were then added to boiling Tris buffer (100 mM, pH 7.75,
4m M EDTA), vortexed, boiled for 2 min and then pelleted by
centrifugation (10000 g for 3 min at 48C). Supernatants
(100 ml) were transferred to clean microcentrifuge tubes and were
kept on ice while covered with aluminium foil. The luciferase
reagent was added in the dark to the cellular extracts and the
microcentrifuge tube was then wiped with an anti-static agent
and placed into a large glass scintillation vial. Photon counts
were obtained over 3 min at 20 s intervals using a Beckman
scintillation counter (model LS5801) programmed to record
single photon events.
Flow cytometric analysis of mitochondrial mass and
function
Cells were seeded in 60 mm glass plates (2610
5 cells/dish in 5 ml
medium) and allowed to attach for 6–8 h. The media was then
replaced with fresh media containing either JC-1 (100 mM)o r
Mitoﬂuor Green (75 nM) (Molecular Probes, Eugene, Oregon),
agents which permit live-cell analysis of mitochondrial function
and mitochondrial mass, respectively (Reers et al, 1995; Kunz-
Schughart et al, 1997). Following loading of the stains, the cells
were incubated at various oxygen tensions for 24–96 h after which
they were trypsinized and analyzed by ﬂow cytometry within
30 min.
MTT assay of mitochondrial function and cell viability
Cells were seeded in 96-well plates (2610
4 cells/well) and allowed
to adhere for 24 h at 378C with 5% CO2 in air. Drugs to be tested
were prepared as stock solutions of 10-fold greater than the
published lethal concentration from which a series of doubling
dilutions was then added to the cells. These agents, together with
their sites of action, are documented in Table 1. Cells were
returned to the incubator for 96 h after which the spent media
was replaced with 200 ml of fresh media containing MTT
(500 mgm l
71) (Cole, 1986; Campling et al, 1991). The cells were
then incubated for an additional 4 h after which they were lysed
with 40% formalin/20% SDS. Cell viability was determined using
an ELISA plate reader set to record absorbance at 600–660 nm.
Data analysis
LC50 values were calculated using the GraphPad Prism program. A
student t-test was used to determine the statistical signiﬁcance of
differences observed.
RESULTS
Mitochondrial membrane potential
To study mitochondrial function, live cells grown under various
oxygen tensions were labelled with the cell permeant, mitochon-
dria-speciﬁc ﬂuorescent probe, JC-1. JC-1 is a lipophilic, cationic,
carbocyanine dye which absorbs light at 490 nm and exists as a
green ﬂuorescent monomer at cellular concentrations below
0.1 mM. However, an intact mitochondrial membrane potential
causes the positively–charged dye to accumulate in the mitochon-
dria where it aggregates to form a red ﬂuorescent dimer. The
ratiometric nature of this probe allows detection of changes in
mitchondrial membrane potential. Depolarization of the mitochon-
drial membrane (i.e., a decrease in mitochondrial function) leads
to a rapid shift from red (emits at 590 nm) to green ﬂuorescence
(emits at 527 nm) as JC-1 ‘spreads out’ from the mitochondria
into the cytosol (Reers et al, 1995; Kunz-Schughart et al, 1997).
This shift from red to green ﬂuorescence is evidenced by the
drop in emission in the red range and a corresponding increase
in the number of counts per cell registered by the ﬂow cytometer
in the green range. The per cent change in membrane potential was
thus derived from a comparison of the counts per cell in the red
range under normoxic conditions with those of the same cell line
under hypoxic conditions 6100.
The hypoxia-sensitive cell line, M010b, showed substantial and
consistent increases in mitochondrial membrane potential as deter-
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Table 1 Metabolic agents and their sites of action
Agent Site/mode of action
Stock concentration
(dilution gradient)
Antimycin A Complex III inhibitor 20 mg ml
71
(0–200 mgm l
71)
CCCP Uncoupler 60 mM
(proton ionophore) (0–600 mM)
Ethidium bromide Nucleic acid intercalator 10 mg ml
71
(0–500 ng ml
71)
FCCP Uncoupler 5 mM
(proton ionophore) (0–50 mM)
Myxothiazol Complex III inhibitor 50 mgm l
71
(0–500 ng ml
71)
Rotenone Complex I inhibitor 10 mM
(0–100 mM)
Sodium azide Complex IV inhibitor 1 M
(0–100 mM)
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of 0.6% oxygen (Figure 1). The mean (+s.e.) per cent increases in
mitochondrial membrane potential for days 1–3 were 16.4+5.6,
38.9+2 and 86.8+3, respectively. In contrast, hypoxia-tolerant
GBM cell lines M006x and M059K showed little change in mito-
chondrial membrane potential following incubation at reduced
oxygen tension. For M006x, the mean (+s.e.) per cent changes
in mitochondrial membrane potential for days 1–3 were
72.7+2, 713.5+1 and 2+3, respectively. For M059K, the mean
(+s.e.) per cent changes in mitochondrial membrane potential for
days 1–3 were 7.7+3, 0.2+1 and 5.1+1, respectively.
Mitochondrial mass
To test whether hypoxia-tolerance simply reﬂects the ability to
generate more mitochondria, we measured mitochondrial mass in
hypoxia-tolerant and -sensitive cells incubated for 1 or 2 days
under aerobic or hypoxic (0.6% oxygen) conditions using Mito-
ﬂuor Green. This cell-permeant, mitochondria selective,
ﬂuorescent dye accumulates in mitochondria regardless of mito-
chondrial membrane potential (Johnson, 1998). No increase in
green ﬂuorescence therefore, no evidence of increased mitochon-
drial biogenesis was observed in any cell line incubated under
normoxic vs hypoxic conditions. Rather, under hypoxic conditions,
mitochondrial mass remained relatively stable, or was slightly
decreased (Figure 1). The mean (+s.e.) per cent changes in mito-
chondrial mass after 1 or 2 days hypoxic incubation were for
M010b, 713.2+8.8 and 711.1+0.9; for M006x, 712.5+4.5
and 79.5+.3, and for M059K, 74.3+2.8 and 711.4+1.4.
ATP measurements
We tested the ability of human GBM cells to maintain intracellular
ATP concentrations when incubated under hypoxic conditions.
Figure 2 shows mean values (+s.e.) calculated for three or more
replicate experiments. When measured after 24 h incubation in
an atmosphere of 0.6% oxygen, the [ATP] of hypoxia–sensitive
M010b cells was equivalent to that of aerobic M010b controls.
However, M010b cells were unable to maintain a stable [ATP]
under prolonged hypoxic conditions, and after 3 days of hypoxia,
the [ATP] was reduced to *60% of day 3 aerobic control values
(33.6+3 vs 20.6+2.7; P50.015). Following 24 h of hypoxia, the
mean [ATP] of hypoxia-tolerant M006x cells was reduced to
72% of control values (33.5+3.3 vs 24.1+4.8; P50.016).
However, under continued hypoxic incubation, the mean [ATP]
M006x cells increased slightly and after 3 days, was not signiﬁcantly
different from that of M006x aerobic controls. M006xLo cells also
showed a decrease in mean [ATP] after 24 h growth in hypoxia,
however this difference was not signiﬁcant. After 3 days of growth
in hypoxia, the mean [ATP] values were similar to that of controls.
Finally, hypoxia-tolerant M059K were able to maintain stable, or
slightly increased [ATP] values throughout the entire hypoxic incu-
bation period. (The large difference in mean [ATP] of M059K cells
as compared to the other cell lines is consistent with the fact that
M059K cells have an *two-fold greater volume than the other cell
lines in this study, and would therefore be expected to contain
proportionately more [ATP]). Importantly, after 3 days of hypoxia,
all of the hypoxia-tolerant cell lines (M006x, M006xLo, M059K)
were able to maintain mean [ATP] equivalent to that of the rele-
vant aerobic control. In contrast, hypoxia-sensitive M010b cells
were unable to maintain stable [ATP].
Sensitivity to mitochondrial poisons
To assess the potential involvement of the mitochondrial electron
transport chain in hypoxia tolerance, we treated human GBM cells
with known chemical inhibitors of mitochondrial function. We
utilized speciﬁc inhibitors of oxidative phosphorylation as well as
general inhibitors of mitochondrial function to distinguish particu-
lar pathway disparities (Table 1). The mitochondrial uncouplers,
FCCP and CCCP, disrupt mitochondrial membrane integrity but
do not affect speciﬁc components of the electron transport chain.
Ethidium bromide is a nucleic acid intercalating agent. Rotenone
is a potent inhibitor of complex I, myxothiazol and antimycin A
are complex III inhibitors, and sodium azide speciﬁcally inhibits
cytochrome c oxidase (complex IV). LC50 values were calculated
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Figure 1 Changes in mitochondrial membrane potential (MMP) (JC-1
ﬂuorescence) and mitochondrial mass (Mitoﬂuor Green ﬂuorescence) in
hypoxia-sensitive (M010b) vs hypoxia-tolerant (M006x, M059K) cell lines.
Cells were grown under normoxic (20% O2) or hypoxic conditions
(0.6% O2) for 1–3 days for MMP determinations, and 1–2 days for mito-
chondrial mass measurements. The per cent change observed in hypoxic
cultures, relative to aerobic controls, is shown. Mean (+s.e.) values calcu-
lated for three separate determinations are shown. Where not displayed,
error bars were too small to plot.
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Figure 2 Cellular [ATP] (pmol cell
71) in human glioma cell lines main-
tained under aerobic or hypoxic (0.6% O2) conditions for 24 or 72 h. Mean
(+s.e.) values calculated for three or more experiments are shown. Where
not displayed, error bars were too small to plot.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 619–624for each drug to facilitate comparison of their effects on mitochon-
drial function. The sensitivities of each cell phenotype (i.e.,
hypoxia-tolerant vs hypoxia-sensitive) was compared by calculating
ratios of the M006x LC50 values divided by the M010b LC50 (stan-
dardized as one) for each agent. Ratios of less than one therefore
indicate a greater sensitivity of M006x cells to the agent tested as
compared to M010b cells. Ratios greater than one indicate an
increased resistance to the test agent for M006x cells. As shown
in Table 2, hypoxia-tolerant and -sensitive GBM cells showed
signiﬁcant differences in their sensitivity to these mitochondrial
poisons. In general, hypoxia-tolerant cells were more sensitive to
inhibitors of mitochondrial function (CCCP, FCCP, rotenone,
sodium azide) or a mitochondrial DNA intercalator, ethidium
bromide (which has been used extensively at low concentrations
to selectively inhibit mitochondrial vs nuclear DNA) (Chandel et
al 1999). However, a notable exception to the overall greater sensi-
tivity of hypoxia-tolerant cells was the relatively greater resistance
of M006x cells to the complex III inhibitors myxothiazol and anti-
mycin A.
DISCUSSION
Although all mammals require oxygen for survival, individual
organ systems vary in their ability to tolerate hypoxic stress. The
normal brain is exquisitely sensitive to oxygen deprivation. In
contrast, a large body of evidence indicates that hepatocytes and
cardiomyocytes can survive brief periods of hypoxia. For example,
hepatocytes exposed to hypoxia (pO2=20 torr) for 3–5 h show no
evidence of cell death (Kinter et al, 1984). Similarly, cardiomyo-
cytes have been shown to maintain viability under hypoxic
conditions ranging from 2–48 h in duration (Chandel et al,
1995; Budinger et al, 1996, 1998). Key features of this metabolic
adaptation to hypoxia have been identiﬁed. They include: (1) the
ability to reversibly suppress oxygen consumption under oxygen
limiting conditions; (2) the ability to maintain cellular [ATP]
throughout the hypoxic period and (3) the ability to maintain a
stable mitochondrial membrane potential under hypoxia
(Hochachka et al, 1996). This suggests that in hypoxia tolerant
cells, ATP synthesis and utilization remain closely coupled. In addi-
tion, while hypoxia produces no acute change in mitochondrial
potential, cytochrome c oxidase (complex IV) undergoes a reversi-
ble decrease in Vmax (Chandel et al, 1995; Budinger et al, 1996,
1998). Further, hypoxia does not alter the overall control exhibited
by NADH over respiration, suggesting that the mechanism respon-
sible for hypoxia tolerance resides exclusively within the
mitochondrial electron transport chain downstream of NADH
(TCA cycle) supply.
The results obtained from study of hypoxia-tolerant hepatocytes
and cardiomyocytes show interesting parallels to our own work.
We have reported previously that cell lines derived from human
GBM specimens vary in their ability to modulate oxygen consump-
tion in hypoxic environments. While hypoxia-tolerant cell lines
such as M006, M006x and M059K were able to decrease their
oxygen consumption as oxygen concentrations declined, oxygen
consumption by the hypoxia-sensitive line, M010b, remained
constant regardless of oxygen availability (Allalunis-Turner et al,
1999). Hypoxia-tolerant hepatocytes and cardiomyocytes exhibit
this property also. Here we report that under reduced oxygen
tensions similar to those that may be encountered in vivo, hypoxia
tolerant GBM cells display two additional characteristics of tissues
adapted to hypoxia: (1) the stabilization of mitochondria
membrane potential and (2) the maintenance of intracellular
[ATP]. In addition, we have shown that ability to maintain near
aerobic [ATP] was not the consequence of generating more mito-
chondria per se. Thus, key components of the hypoxia defence
mechanisms of hypoxia-tolerant normal mammalian tissues are
expressed in hypoxia-tolerant GBM cells.
The co-ordinated activity of many different cellular and
biochemical mechanisms contribute to the development of a
hypoxia-tolerant phenotype. In this study, we examined a putative
role for mitochondria in the development of hypoxia tolerance in
human GBM cells. Although the molecular basis for a cell’s ability
to match oxygen utilization to oxygen availability is unknown, it
has been established that oxygen sensing in mammals, as well as
yeast, likely involves a redox-sensitive haemoprotein. The involve-
ment of the mitochondria in mediating the response to hypoxia
has long been postulated. Current evidence points to a component
of the oxidative phosphorylation (OXPHOS) complex as an
‘oxygen sensor’. Cytochrome bc1 oxidoreductase (complex III),
cytochrome c and cytochrome c oxidase (COX, complex IV) have
all been proposed to play important roles in initial sensing of
oxygen levels (Bunn and Poyton, 1996; Semenza, 1999; Wenger,
2000). The hypoxia-induced increase in turnover rate of the
COX enzyme in yeast (resulting in an increased efﬁciency of elec-
tron transport), has been attributed to the expression of a hypoxia-
speciﬁc COX Vb isoform. In mammalian systems, similar tissue-
speciﬁc variations in speciﬁc COX subunits as well as cytochrome
c have been described and correlated with signiﬁcant differences in
electron transfer kinetics. Furthermore, results of recent studies
using transmitochondrial constructs suggest an oxygen sensing
mechanism driven by the hypoxia-induced generation of reactive
oxygen species (ROS) by complex 3 (Chandel et al, 1998, Chandel
and Schumacker, 1999, 2000).
The signiﬁcantly greater stability of the mitochondrial
membrane potential in M006x and M059K cells indicates a basic
difference in the way these hypoxia-tolerant cell lines react to
oxygen deprivation. Whereas the hypoxia-sensitive M010b cells
increased mitochondrial proton output over a 3 day exposure to
hypoxia, M006x and M059K cells retained a stable membrane
potential despite an oxygen deﬁcit. Intracellular [ATP] was also
maintained at stable levels in M059K and M006x cells until very
low oxygen tensions eventually caused collapse of energy produc-
tion. In contrast, the response of M010b to hypoxic challenge
was to maintain a constant oxygen consumption rate and to
increase mitochondrial membrane potential (i.e., mitochondrial
proton pumping). However, despite these activities, there was no
signiﬁcant increase in intracellular ATP concentration [ATP]. In
fact, after a small initial increase at 24 h, [ATP] dropped signiﬁ-
cantly. This seeming paradox (i.e., a steady oxygen consumption
rate, initially stable [ATP]) leading to an ultimate failure of energy
production may reﬂect large-scale mitochondrial disruption as the
inner mitochondrial membrane dismantles causing both the elec-
tron transport chain and ATP synthase to become non-
functional. In direct contrast, hypoxia-tolerant M006x and
M059K cells maintained a stable mitochondrial membrane poten-
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Table 2 Differential sensitivity of M006x and M0010b cells to mitochon-
drial poisons
Incubation M006x M010b LC50 ratio
Agent time LC50 LC50 6x/10b
Antimycin A 96 h 0.15 mgm l
71 0.08 mgm l
71 1.87
(+0.009) (+0.001)
CCCP 96 h 3.9 mM 9.17 mM 0.43
(+0.08) (+0.34)
Ethidium bromide 96 h 84.45 mgm l
71 482.15 mgm l
71 0.18
(+3.4) (+6.45)
FCCP 96 h 1.16 mM 3.06 mM 0.38
(+0.16) (+0.23)
Myxothiazol 96 h 11.02 mgm l
71 6.84 mgm l
71 1.61
(+0.49) (+0.40)
Rotenone 96 h 4.72 mM 7.3 mM 0.65
(+0.24) (+0.16)
Sodium azide 96 h 0.19 mM 1.32 mM 0.14
(+0.076) (+0.25)
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tions, despite a small initial decrease at the beginning of the
hypoxic exposure. These results suggest that the rate of ATP utili-
zation is being down-regulated to match decreased production
rates as in the Hochachka model (Hochachka et al, 1996).
Most ATP is generated through a proton motive force in
conjunction with mitochondrial ATP synthase and the proton
motive force is itself generated by pumping protons from areas
of low to high concentrations. As the energy required to pump
these protons is generated through the transfer of electrons in
the electron transport chain, our data collectively indicates stabili-
zation of the electron transport chain in hypoxia-tolerant GBM
cells. This would entail a constant proton ﬂow in spite of decreased
electron transport due to the decreased availability of the ﬁnal elec-
tron acceptor, O2. A putative mechanism that may regulate
stabilization of the electron transport chain is expression of
hypoxia-sensitive isoforms of one or more of the molecules in
the electron transport complex as had been described for yeast
(Kwast et al, 1999). In yeast, it has been shown that COX5b, the
hypoxic isoform of COX5, is more efﬁcient at pumping protons
across the inner mitochondrial membrane (i.e., requires less energy
to pump the same number of protons), thereby producing a stable
membrane potential and ATP concentration despite utilizing fewer
oxygen molecules. We are currently investigating the possible
expression of hypoxic isoforms of OXPHOS proteins in our hypox-
ia-tolerant GBM cells.
In addition to examining changes in mitochondrial membrane
potential, we treated cells with a variety of inhibitors of oxidative
phosphorylation and mitochondrial function in an attempt to
uncover differences in the sensitivity of the chemiosmotic system
of the different cell lines. Our results suggest that fundamental
differences exist in the oxidative ‘machinery’ of M006x and
M010b. When compared to hypoxia-sensitive M010b cells,
hypoxia-tolerant M006x cells were more sensitive to agents that
speciﬁcally interfere with aerobic respiration. The exception to this
was the sensitivity to complex III inhibitors myxothiazol and anti-
mycin A. In repeated trials, M006x cells were consistently less
sensitive to these agents than were M010b cells. This difference is
evocative of work by Chandel et al (2000) that demonstrated a role
for complex III generated reactive oxygen species in the stabiliza-
tion of HIF-1a during induction of hypoxia-responsive genes. It
is possible that there is a link between the greater resistance of
hypoxia-tolerant cells to complex III inhibitors and the role of
complex III in the initiation and stable maintenance of hypoxia-
responsive genes which may be responsible for this phenotype.
Experiments are presently underway in our laboratory to investi-
gate the nature of these differences as well as to examine ROS
generation in these glioma cell lines. Additionally, the possible role
of glycolytic and non-mitochondrial determinants of hypoxia toler-
ance to these phenotypes is also being examined.
Spheroid and xenograft studies suggest that most human and
rodent tumour cells are of the hypoxia-sensitive phenotype (Freyer
and Sutherland, 1985; Hlatky et al, 1989). Radiobiological hypoxia
is thought to arise as a consequence of cells continuing to consume
oxygen at a steady rate regardless of the existence of a steep oxygen
gradient with increasing distance from blood supply (Hystad and
Rofstad, 1994; Gulledge and Dewhirst, 1996). If the glucose
concentration in regions distal to the blood supply remains
adequate, some cells can subsist for a short period by utilizing
glycolysis to produce ATP in the absence of oxygen (Freyer and
Sutherland, 1985; Dewhirst et al, 1994). It is these cells, which exist
for a short period of time (usually less than a few hours) in the
narrow hypoxic area adjacent to the necrotic centre of a tumour,
(where glucose concentration also becomes limiting), that resist
the killing effects of ionizing radiation and label with nitroimida-
zole hypoxia markers.
The effect of hypoxia-tolerant cells on a heterogeneous tumour
population may depend on the proportion of such ‘M006x-like’
cells present. If the majority of tumour cells are hypoxia-tolerant,
this would result in a shallower oxygen gradient as these cells
would reduce oxygen consumption when ‘sensing’ decreased
oxygen availability. This, in turn, would permit the diffusion of
oxygen further into a tissue and thus decrease or eradicate areas
that label as radiobiologically hypoxic. This set of conditions offers
a possible explanation for the failure to detect hypoxia in some
large breast tumours (Okunieff et al, 1993). The existence of
hypoxia-tolerant cells in more modest percentages within a larger
population of predominantly hypoxia-sensitive cells could also
have a clinically relevant impact. Cells with a M006x-like pheno-
type could exist in an area of the tumour where both oxygen
and glucose are limiting, thus extending area of radiobiological
hypoxia to the peri-necrotic centre of the tumour. The addition
of even a few additional layers of viable cells could have substantial
clinical consequences and may, in part, explain the extraordinary
radioresistance of glioma tumours in conjunction with their poor
hypoxic labelling in vivo.
In summary, our results indicate that distinct variations in mito-
chondrial function exist between hypoxia-sensitive and -tolerant
GBM cells in response to chemical as well as hypoxic oxidative
challenge. Under normoxic conditions, differences in the OXPHOS
systems of hypoxia-tolerant GBM cells distinguish them from
M010b cells that express normal brain-like responses to hypoxic
challenge. Our models for these studies are human GBM cells that
may not completely mirror the response of normal tissues to
hypoxic insult. In addition, the hypoxia-tolerant and hypoxia-
sensitive phenotypes are broadly deﬁned and their expression
may vary from one human tumour to another. However, studies
such as these may provide insight into the mechanisms utilized
by other types of tumours such as tumours of the cervix, lung,
breast and skin that have been shown to contain hypoxic regions.
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